JP2017530954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530954A5 JP2017530954A5 JP2017511942A JP2017511942A JP2017530954A5 JP 2017530954 A5 JP2017530954 A5 JP 2017530954A5 JP 2017511942 A JP2017511942 A JP 2017511942A JP 2017511942 A JP2017511942 A JP 2017511942A JP 2017530954 A5 JP2017530954 A5 JP 2017530954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- troponin
- use according
- disease
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102000013394 Troponin I Human genes 0.000 claims 6
- 108010065729 Troponin I Proteins 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004987 Troponin T Human genes 0.000 claims 3
- 108090001108 Troponin T Proteins 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 208000029549 Muscle injury Diseases 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 102000004903 Troponin Human genes 0.000 claims 2
- 108090001027 Troponin Proteins 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000005779 cell damage Effects 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 208000037887 cell injury Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010039020 Rhabdomyolysis Diseases 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 238000013130 cardiovascular surgery Methods 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102014216985 | 2014-08-26 | ||
| DE102014216985.2 | 2014-08-26 | ||
| PCT/EP2015/069341 WO2016030323A1 (en) | 2014-08-26 | 2015-08-24 | Use of elafin for disorders associated with elastase independent increase in troponin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530954A JP2017530954A (ja) | 2017-10-19 |
| JP2017530954A5 true JP2017530954A5 (enExample) | 2019-01-24 |
Family
ID=54011022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511942A Pending JP2017530954A (ja) | 2014-08-26 | 2015-08-24 | トロポニンのエラスターゼから独立した増加と関連する障害のためのエラフィンの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (5) | US20180221462A1 (enExample) |
| EP (1) | EP3185892B1 (enExample) |
| JP (1) | JP2017530954A (enExample) |
| WO (1) | WO2016030323A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190060506A1 (en) * | 2017-08-22 | 2019-02-28 | The Board Of Trustees Of The Leland Stanford Junior University | Elafin Incorporated Biomaterials for the Treatment of Chronic Tissue Ulcers |
| WO2021195672A1 (en) * | 2020-03-26 | 2021-09-30 | The Regents Of The University Of California | Detection and treatment of intestinal fibrosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999043308A2 (en) * | 1998-02-27 | 1999-09-02 | Marlene Rabinovitch | Treating pulmonary hypertension through tenascin suppression and elastase inhibition |
| CN1838964A (zh) * | 2002-04-25 | 2006-09-27 | 斯克里普斯研究学院 | 肺病的治疗与预防 |
| GB201003559D0 (en) * | 2010-03-03 | 2010-04-21 | Proteo Biotech Ag | Novel use of elafin |
-
2015
- 2015-08-24 EP EP15756141.6A patent/EP3185892B1/en active Active
- 2015-08-24 US US15/506,481 patent/US20180221462A1/en not_active Abandoned
- 2015-08-24 WO PCT/EP2015/069341 patent/WO2016030323A1/en not_active Ceased
- 2015-08-24 JP JP2017511942A patent/JP2017530954A/ja active Pending
-
2019
- 2019-05-06 US US16/404,441 patent/US20190255158A1/en not_active Abandoned
-
2021
- 2021-12-17 US US17/554,486 patent/US20220133867A1/en not_active Abandoned
- 2021-12-21 US US17/557,874 patent/US20220111021A1/en not_active Abandoned
-
2022
- 2022-12-19 US US18/084,456 patent/US20230285524A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Calvo et al. | Mechanisms and drug development in atrial fibrillation | |
| Brodsky et al. | Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation | |
| Nagai et al. | Urgent Management of Rapid Heart Rate in Patients With Atrial Fibrillation/Flutter and Left Ventricular Dysfunction–Comparison of the Ultra-Short-Acting β1-Selective Blocker Landiolol With Digoxin (J-Land Study)– | |
| JP2015512387A5 (enExample) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| JP2018515101A5 (enExample) | ||
| Gultekin et al. | Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach | |
| Davierwala | Current outcomes of off-pump coronary artery bypass grafting: evidence from real world practice | |
| JP2017530954A5 (enExample) | ||
| WO2022240379A3 (en) | A stable pharmaceutical composition comprising selexipag | |
| Barman | Proarrhythmic effects of antiarrhythmic drugs: case study of flecainide induced ventricular arrhythmias during treatment of atrial fibrillation | |
| DK1728507T3 (da) | Anvendelse af vitamin K for at omvende forkalkning af blodkar | |
| Mahmod et al. | Atrial fibrillation as a complication of dengue hemorrhagic fever: non-self-limiting manifestation | |
| Zhou et al. | Natakalim improves post-infarction left ventricular remodeling by restoring the coordinated balance between endothelial function and cardiac hypertrophy | |
| WO2007047882A3 (en) | Combination of cxcr4 antagonist and morphogen to increase angiogenesis | |
| Dan Kiselnik et al. | Acute myocarditis and myopathy as presenting manifestations of human immunodeficiency virus infection | |
| WO2023130028A8 (en) | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction | |
| RU2014145827A (ru) | Композиция, включающая амлодипин и лозартан, имеющая улучшенную стабильность | |
| Mitsuda et al. | Effect of Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure: A Real-World Study | |
| Vianna et al. | Holt–Oram syndrome: novel TBX5 mutation and associated anomalous right coronary artery | |
| Momomura | Acute rate control in atrial fibrillation with left ventricular dysfunction | |
| Yoon | Cisatracurium besilate | |
| GEORGESCU et al. | COVID-19 AND CARDIOVASCULAR STORM | |
| Sztrymf et al. | Practical management of pulmonary arterial hypertension in the intensive care unit | |
| Payne et al. | D52 MOLECULAR INSIGHT INTO PULMONARY HYPERTENSION: The Matrikine Acetylated Proline-Glycine-Proline (acpgp) Couples Extracellular Matrix Fragmentation To Pulmonary Microvascular Remodeling And Pulmonary Hypertension |